Insmed (INSM) Net Income towards Common Stockholders (2010 - 2026)

Insmed has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$13.3 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 95.87% year-over-year to -$13.3 million in Q2 2026; TTM through Jun 2026 was -$875.3 million, a 15.37% increase from a year earlier, with the FY2025 full-year figure at -$1.3 billion, down 39.73% from the prior year.
• Net Income towards Common Stockholders was -$13.3 million for Q2 2026 at Insmed, up from -$163.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$13.3 million in Q2 2026, with the low at -$370.0 million in Q3 2025.
• Average Net Income towards Common Stockholders over 5 years is -$199.9 million, with a median of -$174.8 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders plunged 155.96% in 2023, then soared 95.87% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at -$160.1 million in 2022, then decreased by 16.2% to -$186.1 million in 2023, then slipped by 26.6% to -$235.5 million in 2024, then plunged by 39.46% to -$328.5 million in 2025, then surged by 95.96% to -$13.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$13.3 million (Q2 2026), -$163.6 million (Q1 2026), and -$328.5 million (Q4 2025), per Business Quant data.